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The presence of porcine endogenous retroviruses presents a potential risk of transmission of infectious
diseases (xenozoonosis) if tissues and organs from genetically modified pigs are to be used in xenotransplan-
tation. Here, we report that intracellular expression of a llama single-domain antibody against p15, the matrix
domain protein of the porcine endogenous retrovirus Gag polyprotein, blocks retrovirus production, providing
the possibility of eliminating the risk of infection in xenotransplantation.
Since there is an evident shortage of human organs for
allotransplantation, xenotransplantation (transplantation of
cells and organs across species) has been considered as a pos-
sible alternative. The pig (Sus scrofa) is the preferred donor
species due to its anatomical and physiological similarities with
humans, breeding characteristics, lower risk of infectious dis-
ease in comparison to primates as organ donors, and ethical
considerations. While most of the known exogenous pathogens
can be controlled by breeding under specific-pathogen-free
conditions, viruses such as porcine endogenous retroviruses
(PERVs) that reside in the pig genome cannot be eliminated
easily and therefore cause concern. Recent studies have shown
that there are approximately 50 proviral integration sites in the
pig genome (18, 25, 35), of which a number occur at the same
position in different pig breeds. This makes a knockout or
breeding strategy for elimination of PERVs impossible.
At least two classes of porcine retroviruses (PERV-A and
PERV-B) are able to infect human cells in vitro (5, 24, 26, 34,
35). Although long-term infection after transplantation has not
been found (4, 9, 14), PERVs are able to infect mouse cells in
vivo (7, 39). Hence there is a possibility that PERVs lead to
malignant, immunosuppressive (8), or other diseases in the
recipient of a porcine transplant and that they may spread
beyond the recipient into the human population, all potential
risks that presently prevent the application of xenotransplan-
tation (21).
While C-type PERVs differ significantly in the env gene
encoding the envelope proteins, the genes for the polymerase
(pol) and the group-specific antigens (gag) show high homology
among all potentially xenotropic classes of PERVs (35). It is
therefore reasonable to assume that antisera raised against
Gag or Pol will react with both xenotropic and polytropic
classes of PERVs (PERV-A and PERV-B) as well as the
ecotropic PERV-C class.
Here, we describe the identification and selection of differ-
ent llama heavy-chain-only antibodies in the form of variable
heavy-chain fragments (VHH) raised against group-specific
antigen Gag. VHHs, with their unique properties, such as high
affinities and solubility in aqueous environments, are in prin-
ciple ideal as intrabodies. We show that intracellular expres-
sion of such antibodies inhibits the production of virus parti-
cles.
MATERIALS AND METHODS
Antigen preparation and immunization. PERV-B gag cDNA (AJ1293657) was
amplified from PK15 cell RNA with the forward primer Gag forward/Asp (5-
ATAGGTACCATGGGACAGACAGTGACTACC-3) and reverse primer Gag
reverse/Hind (5-ATAAGCTTGTCCGAACCCCGTCTCCCCTA-3). The 1.6-kb
gag cDNA was cloned into the pET-30a expression vector (Novagen, Breda, The
Netherlands) and overexpressed upon isopropyl--D-thiogalactopyranoside
(IPTG) induction in Escherichia coli BL21 DE3(pLysS). Purified 60-kDa Gag
protein was used for immunization of a New Zealand rabbit that yielded a
polyclonal rabbit antiserum against the PERV’s Gag. The same protein was used
for the immunization of a young adult male Lama glama. The immunization
schedule was as previously described by van der Linden et al. (40).
Immunoelectron microscopy. PK15 cells were fixed in 4% paraformaldehyde
and prepared for the ultracryotome as previously described (37). Ultrathin cryo-
sections (75 nm) were immunolabeled with llama polyclonal antiserum against
Gag (1:250) followed by the goat anti-llama immunoglobulin G antibody (1:250;
Bethyl Laboratories, Inc.) and rabbit anti-goat antibody conjugated with 10-nm
colloidal gold particles (1:20; Aurion, Wageningen, The Netherlands) as de-
scribed by Geuze et al. (13).
Cloning and expression of Gag cleavage products. DNA encoding p27 capsid
protein was cloned as a SmaI fragment in the pTRCB expession vector (Invitro-
gen). The fragment was amplified from gag cDNA with primers P27 forward/Sma
(5-TCCCCCGGGATCCGCTGCGCACCTATGGCCCT-3) and p27 reverse/
Sma (5-TCCCCCGGGAAAATCTCTCTCTCTCTCCCT-3).
DNA encoding p15 matrix protein was obtained by EagI fragment removal
from the pET-30a-gag construct containing the full-length gag cDNA.
DNA encoding p12 was cloned as an NcoI fragment in pET-30a. The primers
used for its amplification were P12 forward/Nco (5-CATGCCATGGAGATCG
AGGAGCCGCCGATC-3) and P12 reverse/Nco (5-CATGCCATGGGCCAT
AGGTGCGAGCGGTAA-3).
P10 nucleocapsid DNA was cloned as an NcoI fragment in pET-30a. The
primers used for its amplification were P10 forward/Nco (5-CATGCCATGGC
CGCACTGGTTGAAGGGAAG-3) and P10 reverse/Nco (5-CATGCCATGG
ACCCCGTCTCCCCTAATCTT-3).
All clones were transformed into E. coli BL21 DE3(pLysS), in which Gag
cleavage products were overexpressed upon IPTG induction.
Library construction and screening. Total RNA was isolated from peripheral
lymphocytes of the immunized llama with the Ultraspec RNA isolation system
(Biotecx laboratories, Inc., Houston, Tex.). After purification of polyadenylated
RNA (Oligotex 70022; Qiagen), cDNA was made with oligo(dT). DNA fragments
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encoding VHH fragments were amplified by PCR with specific primers Vh1back
SfiI (23) in combination with Lam01 NotI (5-CAGAAATGGAGCGGCCGCC
TTGGGTTTTGGDGGGGAAGAKGAAGACDGATGG-3) or Lam03 NotI
(5-CCTCGGGGTCGCGGCCGCCACRTCCACCACCACRCAYGTGACC
T-3) from exon CH2 and LH NotI (5-GGATTGGGTTGCGGCCGCTGGT
TGTGGTTGTGGTTGTGGTTTTGGTGTCTGGGGTTC-3) from the long
hinge. The amplified VHHs (500 bp) were separated by gel electrophoresis
from the VHs of conventional antibodies containing the CH1 exon (800 bp)
and gel purified. The isolated DNA was SfiI and NotI digested and cloned into
the SfiI and NotI sites of the phagemid vector pHEN1 (15). Transformation into
TG1 electrocompetent cells yielded a llama single-chain antibody library with an
estimated size of 106 recombinants. Two rounds of selection were performed
with panning on antigen adsorbed onto plastic (immunotubes coated with 30 g
and 10 g of purified Gag protein per ml).
BIAcore measurements. Experiments were carried out on a BIAcore 3000
surface plasmon resonance biosensor. Purified Gag protein was immobilized on
a CM5 sensor chip to a level of 600 resonance units (RU, arbitrary binding
response units) with the standard NHS-EDC kit supplied by the manufacturer.
Anti-Myc tag antibody was immobilized on a separate flowcell of the same sensor
chip to a level of 2,400 RU. A flowcell treated with the same procedure but with
no protein was used as a control. The interaction buffer contained 20 mM
HEPES, pH 7.4, 150 mM NaCl, 2 mM EDTA, and 0.005% Tween 20. Dilutions
of different periplasmic fractions in the above buffer were firstly injected over the
anti-Myc surface and adjusted so as to give the same response and thus ensure
that the same amount of anti-Gag VHH was present. The adjusted dilutions of
periplasmic fractions were then passed at the same time over the control and Gag
surfaces, and the response at equilibrium was recorded. The amount of nonspe-
cific binding was small (less than 5% of the specific) and was subtracted from the
specific response. Regeneration of the surfaces was accomplished with a 5-l
pulse of 0.005% sodium dodecyl sulfate, which resulted in complete dissociation
of bound protein and did not affect the binding capacity of the surface for
subsequent interactions. Affinity or kinetic constants could not be obtained
because of the inability to measure the exact concentration of VHH in the
periplasmic fractions, and therefore results are presented as relative Gag binding
at equilibrium.
Cell culture, transfections, and doxycycline induction. The PK15 cells were
grown in Dulbecco’s modified Eagle’s medium/Ham’s F10 (Gibco-BRL) con-
taining 10% fetal calf serum and in later stages supplemented with the appro-
priate selection markers. The Tet-on regulatory plasmid pUHrT 62-1 (generous
gift from H. Bujard) containing the synthetic reverse tetracycline-controlled
transactivator (rtTA2s) sequence was modified by introduction of the puromycin
resistance gene as a eukaryotic selection marker. The resulting plasmid, pUHrT
62-1-puro, was ScaI linearized and transfected into PK15 cells with SuperFect
transfection reagent (Qiagen) according to the manufacturer’s instructions.
Clones were selected on puromycin at 1 g/ml (Sigma, Zwijndrecht, The
Netherlands) and screened in a transient transfection assay with the pBI-EGFP-
Luc reporter plasmid (Clontech). Each clone was tested for luciferase and en-
hanced green fluorescent protein (EGFP) expression with and without doxycy-
cline induction (500 ng/ml). The clone that gave the highest level of luciferase
activity and EGFP expression in the “on” state and no background in the “off”
state was used for the transfection experiments with the antibody coding genes.
After transfection with ScaI-linearized 2xp(A)BiDi-A5-Myc plasmid, clones
were selected and grown in 800 g of G418 (Gibco) per ml. The Tet-on line and
clones 13 and 17 were cultured to 40% confluency in six-well plates with 3 ml of
medium. Doxycycline was added to half of the wells, all the wells were washed
once after 8 h of induction to remove residual virus, and the medium was
replaced for another 48 h of incubation. The cells were collected and used for
Western blot, immunofluorescent staining, and immunoelectron microscopy.
The supernatant was collected for reverse transcription (RT) assays or RT-PCR.
Western blot analysis. Bacterial cell lysates (50 mM Tris, pH 8.0, 150 mM
NaCl, 0.25% NP-40), PK15 viral pellets, and PK15 cell lysates were run on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 12 or 15% gel, blot-
ted, and incubated with A5 single-domain antibody followed by mouse anti-Myc
(1:1,000, clone 9E10; Covance Inc., Princeton, N.J.) and goat anti-mouse immu-
noglobulin-alkaline phosphatase conjugate (1:1,000; Sigma, Zwijndrecht, The
Netherlands).
-Tubulin (56 kDa) was used as a loading control for cell lysates. It was
detected with an anti--tubulin mouse monoclonal antibody (1:2,000; Sigma,
Zwijndrecht, The Netherlands) followed by goat anti-mouse immunoglobulin-
alkaline phosphatase conjugate (ICN Biomedicals BV, Zoetermeer, The Neth-
erlands). Nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate (Roche,
Mannheim, Germany) was used as the alkaline phosphatase substrate.
For visualization of Gag and Gag cleavage products, rabbit anti-Gag poly-
clonal serum or llama anti-Gag polyclonal serum was used, followed by swine
anti-rabbit immunoglobulin-horseradish peroxidase (1:2,000; DAKO) or goat
anti-llama-horseradish peroxidase (1:2,000, Bethyl Laboratories, Inc.). Diamino-
benzidine (Vector Laboratories Inc., Burlingame, Calif.) was used as a substrate.
Immunofluorescence. Cells were grown on coverslips, fixed in 4% paraformal-
dehyde for 20 min, and permeabilized with 0.5% Triton X-100 for 10 min at
room temperature. Gag was visualized with fluorescein isothiocyanate-coupled
goat anti- rabbit immunoglobulin G (Nordic Immunological Laboratories B.V.)
as a secondary antibody. VHH expression was detected with Alexa-594-coupled
goat anti- mouse immunoglobulin G (Molecular Probes). For nuclear staining
4,6-diamino-2-phenylindole (DAPI; Sigma, Zwijndrecht, The Netherlands) was
used.
RT assay. C-type Mn2-dependent RT activity assay was performed on the
cell-free supernatants from each clone in the uninduced and induced states with
the Cavidi HS-kit (Cavidi Tech AB, Uppsala, Sweden) according to the manu-
facturer’s instructions.
RT-PCR. Culture supernatant was harvested and filtered through a 0.45-m-
pore-size filter, and virions were pelleted by ultracentrifugation for 2 h at 150,000
 g/30,000 rpm. Viral RNA was isolated with a commercially available kit
(including a DNase step; Qiagen). cDNA was synthesized with oligo(dT) and
Super RT (HT Biotechnology, Cambridge, United Kingdom). A previously de-
scribed env-specific set of primers for the PCR of PERV-A (pl 206/pl 205) (35),
PERV-B (pl 170/pl 171) (18), and PERV-C (pl 172/pl 173) (18) were used. In
addition, a pol-specific set of primers for A, B, and C type (pol forward, 5-AT
ACTCCCCTGCTACCGGTT-3, and pol reverse, 5CAAGAGGTTATAAGG
GTTCGG 3) were used with the following cycle parameters: 92°C for 4 min, 36
cycles of 92°C for 1 min, 53°C for 1 min, and 72°C for 1 min, followed by 10 min
at 72°C.
p15 epitope mapping. Fragments of p15 DNA were generated by PCR on the
pET-30a gag cDNA plasmid. Aa1 BamHI forward primer was 5-CCGGGGAT
CCCCATGGGACAGACAGTGACTACC-3. Aa46 BamHI reverse primer was
5-GGCGGATCCCGAATGTTGGCCATTCAGAGGCAC-3. Aa113 BamHI
reverse primer was 5-GCGGATCCAGCCAGGATTCGGGGACCTGGC-3.
Aa123 BamHI reverse primer was 5-GGCGGATCCGTGGTGCTCGAGTGC
GGCCGA-3. Aa47 BamHI forward primer was 5-CCGGGGATCCCCATGT
TGGATGGCCATCAGAGGGG-3.
Single-point mutations at amino acids 94 and 96 were generated by PCR on
gag cDNA with primers 5-GCAGAAGATCCT(C3G)CGCCA(T3G)GGGT
TAAACCATGG-3 forward with Aa113 reverse and 5-CCATGGTTTAACCC
(A3C)TGGCG(G3C)AGGATCTTCTGC-3 reverse with Aa1 forward.
A second PCR was performed with the amino acid 1 forward and amino acid
113 reverse primers. The equimolar mixture of the purified fragments from the
above reactions served as a template.
The seven-amino-acid peptide DPPPWVK was made by annealing the follow-
ing oligonucleotides: 5-GATCCCCGATCCTCCGCCATGGGTTAAAG-3
and 5-AATTCTTTAACCCATGGCGGAGGATCGGG-3 with a BamHI over-
hang.
All fragments were cloned into the BamHI site of the expression vector
pGEX.3X (Amersham Pharmacia) and sequenced, and proteins and peptides
were expressed as fusions with glutathione S-transferase by standard protocols
(33).
RESULTS
Reactivity of the Gag-specific antisera. PERV-B gag cDNA
was amplified from porcine PK15 cell RNA and expressed in
bacteria, and the resulting protein was used for the immuni-
zation of a New Zealand rabbit that yielded a polyclonal an-
tiserum against the PERV’s Gag. The same protein was used
for the immunization of a young adult male Lama glama. The
specificity of both the rabbit and llama polyclonal antisera was
tested on Western blots, immunocytochemistry, and immuno-
electron microscopy. Both sera recognize the precursor 60-
kDa Gag polyprotein, intermediate forms, and further pro-
cessed matured forms of the viral structural proteins, including
major capsid (p27), matrix (p15), inner coat, and nucleocapsid
protein. Immunoelectron microscopy on cryosections of PK15
cells showed specific labeling of the virus particles (Fig. 1A).
Based on these results, it was assumed that there would also be
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single-heavy-chain-only antibodies present in the llama that
will react with Gag protein of PERVs.
Isolation of Gag antigen-specific llama VHH antibody frag-
ments, their sequence analysis, and affinity determination. In
order to isolate the genes coding for the llama heavy-chain-
only antibodies, cDNA was synthesized from RNA isolated
from peripheral lymphocytes of the immunized llama and
cloned to yield an immune llama single-chain antibody phage-
mid library of 106 clones. Purified Gag protein was used to
screen the library. Two rounds of selection were performed
with panning on antigen adsorbed onto plastic. The clones
positive in an enzyme-linked immunosorbent assay with anti-
Myc antibody (9E10) for detection of VHHs were analyzed at
the DNA level by HinfI fingerprinting. Eight different clones
(A4, A5, E11, H2, B10, C1, D2, and G12) were obtained and
sequenced (Fig. 2A). They all originated from a long hinge
(IgG2) single-chain antibody of Lama glama and bind to the
Gag protein used for the immunization as well as to the Gag
protein from PK15 cell lysate and the cell-free virus superna-
tant. D2 and G12 bind to the major capsid protein p27, while
A4, A5, B10, C1, H2, and E11 bind to matrix protein p15 (Fig.
1B), and not to p12 or NC, as confirmed by Western blots with
separately expressed cleavage products of Gag polyprotein
(data not shown).
For purification and mass production purposes, all eight
single-domain antibodies were shortened by removal of the
CH2 region and part of the hinge region. This made the his-
tidine tag accessible for purification purposes (on Ni beads)
and resulted in the production of satisfactory amounts of VHH
fragments in the periplasm of bacteria. All eight periplasmic
fractions of the VHHs were shown to be active by BIAcore
analyses (16) in which the Gag antigen was immobilized on
CM5 sensor chips. The binding affinity was in the order E11 
A5  B10  H2  D2  C1  G12  A4 (Fig. 1C).
Tet-on inducible intracellular expression of A5 single-do-
main antibody and its effect on virus production in PK15 cells.
The first high-affinity binder obtained, A5 antibody, was tested
for its capacity to block virus production in PK15 cells. For this
purpose we used the tetracycline-inducible system (Tet-on)
(38). PK15 cells containing the Tet-on regulatory construct
(Fig. 2B) were stably transfected with the A5 single-domain
expression vector (Fig. 2B). Clones were kept on double se-
lection with puromycin and G418. After doxycycline induction,
they were screened for expression of the A5 antibody by im-
munofluorescence with an anti-Myc antibody. The expression
of antibody differed from clone to clone, ranging from a small
percentage of cells expressing in some clones up to a maximum
of 90 to 95% of the cells expressing the A5 VHH (clone 13).
Subcloning or new transfections (also with non-Tet systems)
did not yield any clones where all cells expressed the antibody,
and thus we proceeded with two clones, clone 17 (expressing
the single-domain antibody in 30 to 35% of the cells upon
doxycycline induction) and clone 13 (expressing the single-
domain antibody in 90 to 95% of the cells upon induction).
The Gag antigen could be detected by rabbit polyclonal
antiserum in all of the noninduced cells (Fig. 3, A1, B1, and
C1). It is also detectable in those cells that were induced but
did not express single-chain antibody (Fig. 3, A2-3, B2-3, and
C2-3). Gag is detected at the plasma membrane in a punctate
pattern. However, when the A5 VHH is expressed, the level of
Gag protein drops below the level of detection and the punc-
tate staining pattern at the plasma membrane is lost (Fig. 3,
B2-3, C2-3). The few cells that do not express the VHH after
induction still show such staining. Occasionally, a faint perinu-
clear staining of Gag can be seen in cells expressing the anti-
body domain, indicating that the Gag protein that is still pro-
duced rapidly disappears early in the virus assembly process
(Fig. 3, B3 and C3). This is confirmed by Western blot analysis.
FIG. 1. Lama glama antiserum recognizes Gag and contains sev-
eral VHHs with different affinities for viral Gag. (A) PERV detection
in cryosections of PK15 cells by immunoelectron microscopy with
llama anti-Gag antiserum. (B) Western blot on virus lysate showing
specificity for the 60-kDa Gag polyprotein and for different Gag do-
mains. A4, A5, B10, C1, H2, and E11 are antibodies against matrix
protein p15, while D2 and G12 bind to capsid protein p27. All VHHs
recognize whole Gag. (C) BIAcore affinity measurements. Equal
amounts of soluble reactive VHHs from periplasmic fractions were
used to measure relative binding to Gag protein immobilized on a
BIAcore sensor chip.
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Cell lysates from the Tet-on PK15 cell line, not expressing
the A5 VHH before and after induction, have the same level of
expression of the Gag precursor protein and p27. In the clones
that express the A5 upon doxycycline induction, the viral pro-
teins are reduced proportionally to the number of cells ex-
pressing the antibody in each clone, with -tubulin expression
as a control (Fig. 4B). In both clones (17 and 13), the RT
activity remaining in the supernatant collected from doxycy-
cline-induced, VHH-expressing cells was greatly reduced in
comparison to the supernatant collected from uninduced state
of the same clone or control Tet-on line regardless of its state
of induction. As expected, the largest reduction in RT activity
was observed in the clone with the highest percentage of an-
tibody-expressing cells. RT activity in this case (clone 13) was
reduced to approximately 7% of the activity in uninduced state
(Fig. 4A). This residual RT activity correlates very well with
the number of cells in the cloned population that do not ex-
press the antibody and which still produce virus particles (Fig.
3).
The same experiments were performed with two other
VHHs, E11 and D2. The blocking effect of the E11 VHH was
the same as that of A5, which was predictable from its se-
quence (only one amino acid difference in frame 1) and rec-
ognition of the same epitope. However, the D2 VHH, which
binds to p27 in the PK15 cells, was not blocking virus produc-
tion (data not shown).
Blocking of both PERV-A and PERV-B production. In order
to show that both PERV-A and PERV-B production was
FIG. 2. Amino acid sequences of Gag positive binders and constructs used to express single-domain antibody A5 intracellularly. (A) Alignment
of eight different llama antibodies against the PERV-B Gag protein. The VHH structural elements (complementarity-determining regions [CDRs]
and framework regions [FRs]), hinge region, and CH2 exon are indicated. (B) The vectors used for transfection experiments in PK15 cells. Left:
Tet-on regulatory plasmid pUHrT 62-1-puro. Right: response plasmid 2xp(A)BiDi-A5-Myc, containing A5 VHH in frame with the Myc tag cloned
on one side of the bidirectional Tre-responsive promoter and the neomycin resistance gene.
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blocked, the residual viral RNA in the supernatant was reverse
transcribed and amplified with PERV-A-, B-, or C-specific
primers corresponding to the env sequences or with common
pol primers. As expected, PERV-C particles were not present
in PK15 cells (data not shown). PERV-A and PERV-B envel-
oped particle production by PK15 cells was inversely correlated
with VHH expression based on RT-PCR of serial dilutions of
viral cDNA (Fig. 4C). The results with the pol primers are in
accordance with those for PERV-A and PERV-B particle pro-
duction.
A5 epitope mapping. We partially characterized the epitope
responsible for the inhibitory effect of the A5 single-domain
antibody. A deletional approach revealed that the binding site
for the A5 VHH lies between amino acids 47 and 113 of p15
(Fig. 4D). Two-amino-acid substitution in a highly conserved
PPPWVK motif abolished antibody binding completely. The
A5 antibody did not recognize a short peptide of 7 amino acids
containing this motif in fusion with glutathione S-transferase,
nor did it recognize mouse retrovirus (Cas-Br-M murine leu-
kemia virus) that shared the same motif (data not shown). This
suggests that the motif is part of a larger or conformational
epitope, maybe involving more proximal amino acids that par-
ticipate in alpha helix formation.
DISCUSSION
For xenotransplantation to become a clinical reality, more
than physiological compatibility between pig and human or-
gans is required. The main problem is how to prevent immune
rejection and, one step further, how to prevent a potential
xenozoonosis. PERVs, residing in the pig genome and related
to other retroviruses known to cause leukemias and immune
deficiencies in the infected host, cause the biggest concern.
Even though most of the integrated copies of the PERV ge-
nome are reported to be replication incompetent, there is still
the possibility of recombination and complementation, which
makes a knockout approach (limited to only functional copies
of PERVs) inadequate. There are, however, other methods
that could deal with inhibition of PERVs, such as antiviral
chemotherapy (29), antisense (11), or ribozyme strategies (31),
RNAi (20), active and passive immunization (10), or intracel-
lular expression of inhibitory antibodies.
For therapy to succeed in clinical practice, the therapeutic
agent must have a full blocking effect, be delivered efficiently to
the appropriate cells and/or tissues, and remain there at the
therapeutic level without harming the recipient and the xeno-
transplant. For immunization strategies, the fact that circulat-
FIG. 3. Immunofluorescent staining showing doxycycline-induced production of A5 VHH and its influence on Gag expression. PK15 cells were
stably transfected with the Tet-on regulatory plasmid, so-called Tet-on line (panel A), and two clones, 17 (panel B) and 13 (panel C), of Tet-on
line, which were additionally stably transfected with the response plasmid containing A5 VHH. The cells were either not treated (A1, B1, and C1)
or treated for 48 h with doxycycline (A2, B2, and C2). A3, B3, and C3, same fields as A2, B2, and C2, respectively, of doxycycline-induced cells
showing Gag expression in green and A5 VHH expression in red.
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ing antibodies (against PERV proteins expressed on cell mem-
brane while budding) could contribute to transplant
destruction should be taken into account. Here we describe an
intracellularly expressed single-domain antibody that prevents
virus release from the pig cell. Possible application in xeno-
transplantation would be directed towards “treatment” of the
donor pig strain by means of transgenesis, rather than treat-
ment of the human recipient. However, for the strategy to
succeed, it would be necessary to express the intrabodies ubiq-
uitously at all times. Ubiquitously acting chromatin opening
elements such as hnRNPA2, for example (M. Antoniou, 21
July 1999, PCT/GB99/02357), that regulate genes that need to
be switched on throughout the body could be used as regula-
tory elements in transgenic constructs. In PK15 cell culture
experiments, with a minimal cytomegalovirus promoter, we did
not achieve the desired 100% expression. Since residual RT
activity correlates very well with the number of cells in the
cloned population that do not express the antibody and which
still produce virus particles, it is unlikely that other (as yet
unknown) retroviruses present in PK15 cells contribute to the
residual RT activity. We therefore conclude that our intracel-
lularly expressed antibody against the matrix domain of
PERV-B Gag polyprotein completely blocks virus production
of both PERV-A and -B types of retroviruses in antibody-
expressing PK15 cells.
Although it appears to be early in the process, it is not clear
from our data at which step virus production is blocked. The
antibody interferes with expression of both Gag protein and its
cleavage products, indicating an inhibition of the maturation
process. In several retroviruses analyzed to date, matrix pro-
teins are required for the targeting and interaction of the Gag
precursor with the plasma membrane involving N-terminal
myristylation and a highly basic domain. They function in en-
velope glycoprotein incorporation into budding virions and
virus particle assembly. They also play additional roles during
early and late phases of the viral life cycle (12, 22, 30, 42).
At present, little work has been carried out to specifically
address the function of PERV p15 matrix protein. However,
reports from AIDS research suggest the importance of the
human immunodeficiency virus (HIV) matrix protein (p17) as
a target for antiviral therapies (19, 36). Since the majority of
immunogenic sites on protein antigens are conformationally
dependent and/or discontinuous, they are unlikely to be all
present on short linear peptides. However, a deletional ap-
proach revealed that the binding site for the A5 VHH lies
between amino acid positions 47 and 113 of p15, which ex-
cludes the involvement of the N-terminal myristylation site.
The region shows high sequence conservation among all por-
cine gammaretroviruses, which implies that it is unlikely to be
prone to mutation. However, if the virus mutates, it could
escape antibody inhibition. Our results show that two base-pair
mutations were sufficient to lose the antibody binding capacity.
Thus, using more than one antibody simultaneously against
different epitopes of the virus would be the preferential
method of inhibition.
Whichever step is blocked, our data show that virus produc-
tion can be inhibited by single-domain VHH, the smallest
available intact antigen-binding fragment derived from the
FIG. 4. Virus production (PERV-A/B) by PK15 cells is blocked upon expression of A5 VHH. (A) Relative RT activity in the cell-free
supernatant. White bars represent RT activity in nontreated samples; black bars represent RT activity in supernatants from doxycycline-treated
cells. The decrease in RT activity is proportional to the number of A5 VHH-expressing cells. (B) Western blot showing Gag expression in cell
lysates upon doxycycline induction in the different clones. Within each clone -tubulin is stained as a loading control. (C) RT-PCR of serially
diluted viral cDNA preparations. The 2, 0.4, and 0.08 refer to microliters of template used in the reaction. The gel was stained with ethidium
bromide. Both PERV-A and PERV-B are blocked (25-fold decrease) by the expression of A5 VHH. (D) A5 epitope mapping, showing that the
A5 binding site lies between amino acids 47 and 113 of the PERV matrix protein.
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functional immunoglobulin, without cytotoxicity. The genetic
modifications of pigs, such as knocking out the gene coding for
-1,3-galactosyltransferase (6, 17, 27) and expressing human
complement regulatory proteins (2, 3, 28), appear to have
overcome the hyperacute rejection problem. At the same time,
knocking out -1,3-galactosyltransferase from pigs might cre-
ate an even greater risk of potential xenozoonosis caused by
PERVs (1). Since PERV particles containing the pig cell mem-
brane do not have the -1,3-galactosyltransferase epitope on
their surface anymore, virus emerging from the xenotransplant
from knockout pigs will be less susceptible to inactivation by
virus neutralizing human anti -1,3-galactosyltransferase anti-
bodies (32). The same is true for pigs transgenic for human
CD46, CD55, or CD59. Viruses produced in such pigs would
carry these molecules on their cell surface, thereby escaping
complement-mediated virolysis (41). In the background of ge-
netically modified pigs mentioned above, the ubiquitous trans-
genic expression of antiviral single-domain antibodies such as
the one described in this paper will contribute greatly to a
solution of the safety problem presented by PERVs.
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